New Clinical Study Suggests The Use Of OraPharma's ARESTIN Microspheres, 1mg May Decrease Certain Pathogens In Adults With Periodontitis
Portfolio Pulse from Happy Mohamed
Bausch Health Companies Inc. (BHC) and OraPharma announced a new study showing that ARESTIN microspheres, 1mg decreased certain pathogenic burdens in adults with periodontitis when applied after scaling and root planning (SRP) and at a three-month reapplication. The study was published in the Journal of Periodontology.
May 18, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bausch Health's new study on ARESTIN microspheres shows positive results in decreasing pathogenic burdens in adults with periodontitis, potentially boosting the product's demand.
The study demonstrates the effectiveness of Bausch Health's ARESTIN microspheres in reducing pathogenic burdens in adults with periodontitis. This positive result may lead to increased demand for the product, which could positively impact Bausch Health's revenues and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100